Aegerion Pharmaceuticals, Inc. (AEGR) reported first quarter 2013 net loss per share of 64 cents, narrower than the Zacks Consensus Estimate of a loss of 72 cents, but...(read more
Aegerion Pharmaceuticals, Inc. (AEGR) recently provided more details on its public offering. The offering is expected to close on Jan 16, 2013.
The total offer consists of...(read more
Aegerion Pharmaceuticals has received federal orphan drug status for its lead candidate, a treatment for people with severe lipid disorders.
Orphan drug status is given to drugs that...(read more